🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06550024
Active, not recruiting Not applicable

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

NCT06550024 · tracked via the Priya Life Science UK tracker
Sponsor
CrannMed
Phase
Not applicable
Started
2024-11-28
Last updated
2026-03-18

Condition(s) studied

Osteo Arthritis KneeJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesArthritisOsteoarthritis

Investigational drug(s) / intervention(s)

SakuraBead Resorbable MicrospheresCorticosteroid Injection

SakuraBead Resorbable Microspheres: Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres

Corticosteroid Injection: Corticosteroid injection in the knee

Study summary

An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

Eligibility

Sex
ALL
Min age
40 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subject is able and willing to provide written informed consent, and 2. Clinical diagnosis of knee OA, and 3. Moderate to severe knee pain (WOMAC Pain ≥ 10), and 4. Pain refractory to at least 3 months of conservative therapies (anti-inflammatory drugs, or physical therapy, or intra-articular injections), and 5. Kellgren-Lawrence grade 1, 2 or 3 on radiograph of the knee, and 6. Age ≥ 40 years and \< 80 years, and 7. Able to comply with all treatments and follow-up visits. Exclusion Criteria: 1. Severe knee OA (Kellgren-Lawrence grade 4), or 2. Current infection of target joint, or 3. Life expectancy less than 36 months, or 4. Known advanced atherosclerosis as defined by history of lower extremity or pelvis arterial bypass graft, lower extremity or pelvis arterial stent placement or prior history of vascular claudication, or 5. Rheumatoid or known serologic diagnosis of autoimmune arthritis, or 6. Prior knee replacement surgery in the target knee, or 7. Pain score of \>3 NRS on the non-target knee, or 8. An acute internal derangement of the target knee, or 9. History of uncorrectable coagulopathy, or 10. Prior iodinated contrast reaction resulting in anaphylaxis, or 11. Active pregnancy as demonstrated by urine or serum β-hCG, or lactating female, or planning pregnancy in the following 12 months, or 12. Has undergone an invasive treatment (including but not limited to: corticosteroid injection, hyaluronic acid injections, nerve ablation) in the target knee within the past 3 months, or 13. Contraindication to MRI, or 14. At the discretion of the Principal Investigator

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
University of Alabama Medicine Birmingham Alabama
Harbor UCLA Medical Center Torrance California
Advanced Vascular Institute Panama City Florida
IR Centers Raleigh North Carolina
IR Centers Leesburg Virginia
Bokhua Memorial Cardiovascular Center Tbilisi Georgia
Royal Berkshire NHS Foundation Trust Reading United Kingdom
Nano Medical Clinic Tashkent Uzbekistan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06550024 on ClinicalTrials.gov ↗ ← All trials in the UK